Trexquant Investment LP Increases Stock Holdings in ICU Medical, Inc. $ICUI

Key Points

• Trexquant Investment LP raised its stake in ICU Medical by 41.1%, acquiring a total of 22,740 shares worth approximately $3.16 million by the end of the first quarter.
• Insider trading activity saw CEO Vivek Jain purchase 21,929 shares, increasing his ownership by 20.26%, while Director David C. Greenberg acquired 1,200 shares, boosting his ownership by 17.75%.
• ICU Medical's quarterly earnings report showed earnings per share of $2.10, exceeding estimates, yet the company's revenue fell 8% year-over-year, with analysts setting an average price target of $179.00 for the stock.

Trexquant Investment LP raised its stake in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 41.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 22,740 shares of the medical instruments supplier's stock after purchasing an additional 6,623 shares during the quarter. Trexquant Investment LP owned 0.09% of ICU Medical worth $3,158,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of ICUI. GAMMA Investing LLC grew its stake in shares of ICU Medical by 27.2% in the 1st quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier's stock valued at $99,000 after purchasing an additional 153 shares during the last quarter. Blue Trust Inc. grew its stake in shares of ICU Medical by 23.0% in the 1st quarter. Blue Trust Inc. now owns 801 shares of the medical instruments supplier's stock valued at $111,000 after purchasing an additional 150 shares during the last quarter. Vontobel Holding Ltd. purchased a new position in shares of ICU Medical in the 1st quarter valued at approximately $235,000. Xponance Inc. grew its stake in shares of ICU Medical by 5.3% in the 1st quarter. Xponance Inc. now owns 1,714 shares of the medical instruments supplier's stock valued at $238,000 after purchasing an additional 86 shares during the last quarter. Finally, Tidal Investments LLC purchased a new position in shares of ICU Medical in the 4th quarter valued at approximately $342,000. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at ICU Medical

In related news, Director David C. Greenberg purchased 1,200 shares of the business's stock in a transaction dated Wednesday, August 27th. The stock was bought at an average cost of $126.42 per share, with a total value of $151,704.00. Following the completion of the acquisition, the director directly owned 7,960 shares in the company, valued at $1,006,303.20. The trade was a 17.75% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Vivek Jain purchased 21,929 shares of the business's stock in a transaction dated Thursday, August 14th. The stock was bought at an average cost of $112.84 per share, with a total value of $2,474,468.36. Following the completion of the acquisition, the chief executive officer owned 130,149 shares of the company's stock, valued at approximately $14,686,013.16. The trade was a 20.26% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 1.50% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Raymond James Financial lowered their target price on ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating on the stock in a research note on Friday, August 8th. Wall Street Zen raised ICU Medical from a "hold" rating to a "buy" rating in a report on Friday. Finally, Piper Sandler initiated coverage on ICU Medical in a report on Friday, August 15th. They issued an "overweight" rating and a $145.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $179.00.

ICU Medical Price Performance

ICUI stock traded up $5.61 during midday trading on Friday, hitting $131.24. 280,702 shares of the stock were exchanged, compared to its average volume of 376,226. The stock's 50-day moving average price is $126.51 and its 200-day moving average price is $134.61. The stock has a market cap of $3.24 billion, a price-to-earnings ratio of -86.34 and a beta of 0.86. ICU Medical, Inc. has a fifty-two week low of $107.00 and a fifty-two week high of $196.26. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.17 and a current ratio of 2.44.

ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.44 by $0.66. The firm had revenue of $543.57 million during the quarter, compared to analysts' expectations of $543.33 million. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.ICU Medical's revenue was down 8.0% on a year-over-year basis. During the same period in the previous year, the firm posted $1.56 earnings per share. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. Research analysts predict that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.